Understanding the Current Rating
The Strong Sell rating assigned to Syngene International Ltd indicates a cautious stance for investors, suggesting that the stock is expected to underperform relative to the broader market and its peers. This recommendation is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. Each of these factors contributes to the overall assessment of the company’s investment potential as of today.
Quality Assessment
As of 11 February 2026, Syngene International Ltd maintains a good quality grade. This reflects the company’s operational strengths and business fundamentals, including its established presence in the healthcare services sector. Despite this, the quality grade alone is insufficient to offset concerns arising from other parameters. The company’s net sales have grown at an annualised rate of 11.77% over the past five years, which is moderate but not robust enough to drive strong investor confidence. Operating profit growth has been even more subdued, at 5.36% annually, indicating challenges in scaling profitability effectively.
Valuation Considerations
Valuation is a critical factor influencing the Strong Sell rating. Currently, Syngene International Ltd is classified as very expensive with a price-to-book value of 3.9. This premium valuation is notably higher than the average historical valuations of its peers in the healthcare services sector. The stock’s elevated valuation is difficult to justify given the company’s recent financial performance and growth prospects. Investors should be wary of paying a premium for a stock that is not demonstrating commensurate earnings growth or return on equity (ROE), which stands at a modest 9.9% as of today.
Financial Trend Analysis
The financial trend for Syngene International Ltd is currently negative. The latest quarterly results for December 2025 reveal a significant decline in profitability. Profit before tax (excluding other income) fell by 37.8% to ₹83.60 crores compared to the previous four-quarter average. Net profit after tax dropped even more sharply by 55.3% to ₹52.29 crores, with earnings per share (EPS) hitting a low of ₹0.37. These figures highlight a deteriorating earnings trajectory, which is a key concern for investors evaluating the stock’s future potential.
Technical Outlook
From a technical perspective, the stock is currently rated bearish. This reflects the downward momentum observed in the share price over recent months. As of 11 February 2026, Syngene’s stock has declined by 0.87% on the day, but more notably, it has lost 27.18% over the past month and 36.91% over the last year. The stock’s underperformance extends to longer time frames as well, with a 29.23% decline over three months and a 28.93% drop over six months. This sustained negative price action signals weak investor sentiment and technical weakness, reinforcing the Strong Sell rating.
Performance Relative to Benchmarks
Syngene International Ltd’s returns have lagged behind key market indices such as the BSE500 over multiple periods. The stock’s one-year return of -36.91% contrasts sharply with broader market performance, underscoring its underperformance. Additionally, the company’s profits have contracted by 18.5% over the past year, further compounding concerns about its growth and earnings stability. This combination of poor returns and declining profitability presents a challenging investment case.
Implications for Investors
The Strong Sell rating suggests that investors should exercise caution with Syngene International Ltd at this time. The company’s high valuation, coupled with weakening financial trends and bearish technical signals, indicates limited upside potential and elevated risk. While the company’s quality remains good, it is insufficient to counterbalance the negative factors currently weighing on the stock. Investors seeking exposure to the healthcare services sector may wish to consider alternatives with stronger financial momentum and more attractive valuations.
Summary of Key Metrics as of 11 February 2026
- Mojo Score: 28.0 (Strong Sell grade)
- Market Capitalisation: Smallcap
- Price to Book Value: 3.9 (Very Expensive)
- Return on Equity (ROE): 9.9%
- Net Sales Growth (5 years CAGR): 11.77%
- Operating Profit Growth (5 years CAGR): 5.36%
- Profit Before Tax (Dec 2025 quarter): ₹83.60 crores (-37.8% vs previous 4Q average)
- Profit After Tax (Dec 2025 quarter): ₹52.29 crores (-55.3% vs previous 4Q average)
- Earnings Per Share (EPS) (Dec 2025 quarter): ₹0.37 (lowest recent level)
- Stock Returns: 1D +0.87%, 1M -27.18%, 1Y -36.91%
Our latest weekly pick is live! This Large Cap from Diamond & Gold Jewellery comes with clear entry and exit targets. See the detailed report with target price now!
- - Clear entry/exit targets
- - Target price revealed
- - Detailed report available
Sector and Market Context
Operating within the healthcare services sector, Syngene International Ltd faces competitive pressures and evolving market dynamics. The sector often demands consistent innovation and operational efficiency to sustain growth. Currently, Syngene’s financial and technical indicators suggest it is struggling to keep pace with sector peers. Its premium valuation relative to earnings and book value is not supported by commensurate growth or profitability, which is a critical consideration for investors in this space.
Conclusion
In summary, Syngene International Ltd’s Strong Sell rating by MarketsMOJO reflects a comprehensive evaluation of its current financial health, valuation, and market performance as of 11 February 2026. While the company retains good quality fundamentals, its very expensive valuation, negative financial trends, and bearish technical outlook collectively advise caution. Investors should carefully weigh these factors when considering exposure to this stock, recognising the risks inherent in its current profile.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
